Abstract

An antitumor agent according to the present disclosure contains, as an active ingredient, at least one component selected from the group consisting of ribozyme nucleic acids, antisense nucleic acids, RNAi-inducing nucleic acids, dominant negative variants, and aptamers, and vectors that express the same.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided is a method for efficiently producing heterologous T cell receptor or chimeric antigen receptor gene-introduced leukocytes.　The present invention relates to: a method for producing modified leukocytes, such as T cells to which heterologous a T-cell receptor or a chimeric antigen receptor gene has been introduced, by adding a ferroptosis inhibitor during the production step; and modified leukocytes produced by the method according to the present invention.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/13 - Immunoglobulins
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The objective of the present invention is to alleviate a work load at the time of start-up in a prediction system equipped with a reservoir. This prediction system includes: a calibration-verified AI device in which a plurality of physical reservoirs for processing time-series signals are connected to each other; and a trained prediction device that reads outputs from the plurality of physical reservoirs included in the calibration-verified AI device while adding reading weights and outputs a predicted value. The calibration-verified AI device has the plurality of physical reservoirs verified to be calibrated so that the physical properties of the physical reservoirs are the same by adding M-series noise to the time-series signals. The trained prediction device has read weights duplicated from another trained prediction device that reads outputs from a plurality of other physical reservoirs having the same physical properties as the plurality of physical reservoirs while adding reading weights and outputs a predicted value, and that has read weights updated by training.

IPC Classes  ?

• G06N 3/044 - Recurrent networks, e.g. Hopfield networks
• G06N 3/065 - Analogue means

Abstract

The purpose of the present invention is to provide an annular device that, in comparison to convention annular devices, suppresses the effects of frictional force which occurs between the annular device and the palpebral conjunctiva during blinking, and that has excellent stability on the eyeball when worn. This purpose is achieved by, for example, an annular device that is to be worn on the surface of the sclera and that comprises: an opening which exposes the cornea; and main body which has a non-slab-off region and a slab-off region formed such that the maximum thickness thereof gradually decreases from a right end part side to an upper end part side and to a lower end part side, and from a left end part side to the upper end part side and to the lower end part side.

IPC Classes  ?

• A61F 9/007 - Methods or devices for eye surgery

Abstract

Provided is a particle beam treatment system capable of more effectively radiating a particle beam. This particle beam treatment system comprises: a radiation device 25 for radiating particle beams B1, B2; and a control device 40 for controlling the radiation device. The control device causes the plurality of particle beams B1, B2, which are for different purposes but are of the same type, to be radiated from the radiation device to an irradiation subject 31 at different timings.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• G21K 5/04 - Irradiation devices with beam-forming means

Abstract

The purpose of the invention described herein is to provide a compound having a novel chemical structure that is usable for lipid nanoparticles. Disclosed are a compound represented by formula (I) (in the formula, R1and R2are each independently a C10-24 chain hydrocarbon group, R3 is a C1-22 chain hydrocarbon group) and lipid nanoparticles containing the compound.

IPC Classes  ?

• C07F 9/09 - Esters of phosphoric acids
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

33 (0 ≤ x ≤ 0.5) or PLTZ.

IPC Classes  ?

• H10N 30/853 - Ceramic compositions
• H10N 30/076 - Forming of piezoelectric or electrostrictive parts or bodies on an electrical element or another base by depositing piezoelectric or electrostrictive layers, e.g. aerosol or screen printing by vapour phase deposition
• H10N 30/88 - MountsSupportsEnclosuresCasings

Abstract

Provided is a compound which is synthesized using an amino acid that can be easily procured in the marketplace and used industrially, has activity for inhibiting adhesion of fouling present in sea water, and has low toxicity. The present invention relates to: a dipeptide containing a proline residue which is represented by formula (1), or a tripeptide containing a proline residue and a phenylalanine residue [in the formula, R13-103-10 hydrocarbon group, R2and R31-81-8 hydrocarbon group or the like, and R41-61-6 hydrocarbon group or the like]; and a composition for inhibiting adhesion of marine fouling, which contains this compound.

IPC Classes  ?

• C07K 5/097 - Tripeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp, e.g. thyroliberin, melanostatin
• A01N 43/36 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
• A01P 7/00 - Arthropodicides
• A01P 9/00 - Molluscicides
• C07K 5/078 - Dipeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp

Abstract

122 includes a dichloroacetyl group.) These copolymers or polymeric micelles which are formed from these copolymers in an aqueous medium have a tumor-specific radiation enhancement effect and enhance the therapeutic effect of radiation therapy on tumors. Consequently, the present invention provides a medical use of these copolymers or polymeric micelles for exerting such an effect.

IPC Classes  ?

• C08G 81/00 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
• A61K 9/10 - DispersionsEmulsions
• A61K 9/51 - Nanocapsules
• A61K 31/765 - Polymers containing oxygen
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

outoutoutoutoutvfnoisefgfg of the floating gate transistor FG in accordance with the probability p.

IPC Classes  ?

• G11C 11/54 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using elements simulating biological cells, e.g. neuron
• G06F 7/58 - Random or pseudo-random number generators
• G06G 7/60 - Analogue computers for specific processes, systems, or devices, e.g. simulators for living beings, e.g. their nervous systems
• G11C 16/04 - Erasable programmable read-only memories electrically programmable using variable threshold transistors, e.g. FAMOS

Abstract

The present invention pertains to a dehydrogenation catalyst for producing propylene by a dehydrogenation reaction of propane, said catalyst comprising MFI type zeolite, elemental platinum, and elemental M, wherein: the molar ratio (Si/Al) of silicon to elemental aluminum of the MFI type zeolite is 50 or more; the elemental M is at least one element selected from the group consisting of elemental germanium, elemental copper, elemental indium, elemental iron, elemental ruthenium, and elemental rhenium; and the elemental platinum and the elemental M are located in a channel of the MFI type zeolite.

IPC Classes  ?

• B01J 29/035 - Crystalline silica polymorphs, e.g. silicalites
• B01J 37/08 - Heat treatment
• B01J 37/10 - Heat treatment in the presence of water, e.g. steam
• B01J 37/18 - Reducing with gases containing free hydrogen
• C07B 61/00 - Other general methods
• C07C 5/333 - Catalytic processes
• C07C 11/06 - Propene

Abstract

This collagen yarn contains collagen nanofibrils, and has a diameter of 10-50 μm and a total length of 2 × 105times or more greater than the diameter, wherein the collagen nanofibrils exhibit high alignment properties along the longitudinal direction of the collagen yarn, the high alignment properties are indicated by a fact that the refractive index difference determined by a birefringence measurement performed on a hydrated collagen yarn is 4.3 × 10-4 or more, and the hydrated collagen yarn is obtained by immersing the collagen yarn in a neutral phosphate buffer solution.

IPC Classes  ?

• D01F 4/00 - Monocomponent artificial filaments or the like of proteinsManufacture thereof
• A61L 27/24 - Collagen
• D01D 5/06 - Wet spinning methods

Abstract

Provided are a pressure sensor and the like that are capable of accurately detecting, as a surface, a pressure applied to an object from the outside.　The present invention is provided with: a plurality of sensor pixels PX that are arranged in a surface formation, the sensor pixels PX being each equipped with a membranous pressure-sensitive film 2 having a resistance value that varies by the front surface of the pressure-sensitive film 2 being pressed, and a first electrode layer 4 and a second electrode layer 6 laminated only on the back surface of the pressure-sensitive film 2; and a drive circuit that drives each of the sensor pixels PX, the drive circuit detecting, according to variations in the resistance values caused by pressing the plurality of sensor pixels PX, the pressure of the pressing for each of the sensor pixels PX.

IPC Classes  ?

• G01L 5/00 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes

Abstract

The present invention enables easy acquisition of an excellent electrical contact while using electrodes made of a metal other than thallium.　A radiation detector 1 is provided with: a crystal 2 containing thallium bromide as the main component; and electrodes 3 and 4 which are in contact with the crystal 2 so as to sandwich the crystal 2 therebetween in an X direction and which are made of a metal other than thallium. Portions of the crystal 2 in contact with the electrodes 3 and 4 are doped with at least one of strontium, lead, thallium, and bromine.

IPC Classes  ?

• G01T 1/24 - Measuring radiation intensity with semiconductor detectors
• C30B 11/00 - Single-crystal-growth by normal freezing or freezing under temperature gradient, e.g. Bridgman- Stockbarger method
• C30B 13/00 - Single-crystal growth by zone-meltingRefining by zone-melting
• C30B 29/12 - Halides

Abstract

Provided are: a positive electrode body of a solid electrolytic capacitor that has a high withstand voltage and a low leakage current; a solid electrolytic capacitor; a method for manufacturing the positive electrode body of the solid electrolytic capacitor; and a method for manufacturing the solid electrolytic capacitor. This positive electrode body comprises: a valve action metal substrate; and a dielectric oxide film on the valve action metal substrate. The dielectric oxide film comprises: a void layer on a surface layer side of the dielectric oxide film; and a void repair layer on the side of the dielectric oxide film that interfaces with the valve action metal substrate. This positive electrode body is formed by first chemical conversion processing, void introduction processing, and second chemical conversion processing. In the first chemical conversion processing, a prescribed chemical conversion voltage is applied to the valve action metal substrate. In the void introduction processing, the positive electrode body is immersed in one or more of an acidic solution, an alkaline solution, and pure water. In the second chemical conversion processing, a chemical conversion voltage lower than that of the first chemical conversion treatment is applied.

IPC Classes  ?

• H01G 9/07 - Dielectric layers
• H01G 9/00 - Electrolytic capacitors, rectifiers, detectors, switching devices, light-sensitive or temperature-sensitive devicesProcesses of their manufacture

Abstract

Provided is a cathode electrode catalyst for ammonia electrosynthesis that contains a perovskite-type metal oxynitride. The perovskite-type metal oxynitride includes, as main metal elements: A, which is at least one element selected from the group consisting of Ba, Sr, and Ca and which contains 50 mol% or more of Ba; and Mo or B, which is at least one element selected from the group consisting of Ta, Nb, and W. The perovskite-type metal oxynitride satisfies a prescribed formula.

IPC Classes  ?

• C25B 11/073 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material
• B01J 27/24 - Nitrogen compounds
• C01C 1/04 - Preparation of ammonia by synthesis
• C25B 1/27 - Ammonia

Abstract

Provided is a treatment support system capable of easily determining a radiation treatment device desirable for a patient. An arithmetic processing device 101 predicts a treatment effect index for each treatment modality of a radiation treatment device 202 by using a region of interest which corresponds to a part related to the irradiation of a patient with radioactive ray in a three-dimensional fluoroscopic image showing the patient, and also using parameter information which indicates a value of a parameter for the prediction of a treatment effect index for evaluating the effect of a radiation treatment for each treatment modality of the radiation treatment device 202 for performing the radiation treatment.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

Provided is a curette having the function of making it possible to easily confirm the orientation of an affected site surface in a body cavity. This curette comprises: a shaft part 2 that extends in a linear rod shape; and a head part 3 that is provided at the tip end of the shaft part 2. The shaft part 2 is provided with a posture recognition part 5 that, if the head part 3 is at a surface, can recognize the vertical direction n1 of said surface and, if the head part 3 is not at a surface, can recognize the direction in which the tip of the head part is pointing.

IPC Classes  ?

• A61B 17/56 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor

Abstract

This cement composition for fixing carbon dioxide contains a cement composition and a carbon dioxide absorption liquid containing a carbon dioxide absorbent. This cement hardened body for fixing carbon dioxide includes a cement hardened body and a carbonate carried on the cement hardened body. This method for fixing carbon dioxide has: a step for kneading a carbon dioxide absorption liquid containing a carbon dioxide absorbent into a cement composition; a step for hardening the cement composition containing the carbon dioxide absorbent to obtain a cement hardened body for fixing carbon dioxide; and a step for bringing the atmosphere into contact with the cement hardened body for fixing carbon dioxide, and fixing the carbon dioxide contained in the atmosphere to the cement hardened body for fixing carbon dioxide.

IPC Classes  ?

• C04B 28/02 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing hydraulic cements other than calcium sulfates
• C04B 24/12 - Nitrogen containing compounds
• C04B 40/02 - Selection of the hardening environment

Abstract

Disclosed is a polymer material that comprises: a cyclic polymer which has one or more annular parts; and a crosslinked polymer which has a plurality of linear parts, and in which the plurality of linear parts are bonded to each other at crosslinking points so as to form a crosslinked body. At least some of the cyclic polymers in the polymer material each have an annular part that is penetrated by a linear part of the crosslinked polymer. The ratio of the amount of the cyclic polymer to the amount of the crosslinked polymer may be 15% by mass or more.

IPC Classes  ?

• C08L 101/00 - Compositions of unspecified macromolecular compounds
• C08L 83/04 - Polysiloxanes

Abstract

Provided are: an amino acid compound, for scanning, capable of rapidly synthesizing a modified peptide and assessing the activity of the modified peptide; a modified peptide for scanning; a kit for scanning; and a scanning method for active sites in a peptide. This amino acid compound for scanning is to be used for scanning active sites in a peptide when being introduced so as to substitute a portion of amino acids in a peptide, and is a compound having, in a portion of the structure thereof, a 1,2-amino alcohol or is a substitution product of the same. The present invention also pertains to a modified peptide for scanning, a kit for scanning, and a scanning method for active sites in a peptide.

IPC Classes  ?

• C07C 271/34 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 31/04 - Antibacterial agents
• C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• C07K 1/04 - General processes for the preparation of peptides on carriers

Abstract

This structural color member (1) has a base material (2) and an oxide film (3) that is formed of a metal oxide and that covers the base material (2). The oxide film (3) includes a porous layer (31) that includes a plurality of pores (311) and that is disposed on the base material (2), and a dense layer (32) that does not include the pores (311) and that is laminated on the porous layer (31). When the thickness of the oxide film (3) is measured at various positions, the thickness of the oxide film (3) at each measurement position is within the ranges of 150 nm to 1000 nm and 0.75 times to 1.25 times the average value of the thickness of the oxide film (3).

IPC Classes  ?

• C23C 28/00 - Coating for obtaining at least two superposed coatings either by methods not provided for in a single one of main groups , or by combinations of methods provided for in subclasses and
• B32B 7/023 - Optical properties
• B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
• C25D 11/26 - Anodisation of refractory metals or alloys based thereon

Abstract

This adsorbent contains a copolymer of a cationic functional group-containing monomer or an anionic functional group-containing monomer and an aromatic group-containing monomer, the copolymer having a specific structure in at least a part thereof.

IPC Classes  ?

• B01J 20/26 - Synthetic macromolecular compounds
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• C02F 1/28 - Treatment of water, waste water, or sewage by sorption
• C08F 8/44 - Preparation of metal salts or ammonium salts
• C08F 220/10 - Esters

Abstract

Provided are: a pH-sensitive cationic lipid which can be more easily synthesized through a small number of steps without requiring any organometal reaction or use of any relatively expensive starting materials; and lipid nanoparticles including the lipid. Disclosed is a pH-sensitive cationic lipid comprising a compound represented by general formula (I) or (I'). R1, Z2, s, Z1, and X are as defined in the description.

IPC Classes  ?

• C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Abstract

This method for producing fine particles involves hydrolysis in a reaction solution that includes intermediate particles, a hydrolytic enzyme, and a solvent including water, wherein: the intermediate particles have two or more hydrophobic core parts and a linking group linking the two or more core parts; the linking group has a hydrolyzable group; and the hydrolyzable group is hydrolyzed to form fine particles including one or more core parts and having an average particle diameter smaller than the average particle diameter of the intermediate particles.

IPC Classes  ?

• C12P 1/00 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes

Abstract

The present invention pertains to a pharmaceutical composition for preventing or treating refractory bone defects, the pharmaceutical composition comprising: human dental pulp stem cells; and a porous scaffold material having bone-inducing ability. Preferably, the human dental pulp stem cells are cultured together with the scaffold material, and are applied to a bone defect part to assist in the regeneration of bone tissue containing cancellous bone.

IPC Classes  ?

• A61K 35/32 - BonesOsteocytesOsteoblastsTendonsTenocytesTeethOdontoblastsCartilageChondrocytesSynovial membrane
• A61K 47/02 - Inorganic compounds
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61L 27/12 - Phosphorus-containing materials, e.g. apatite
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/20 - Polysaccharides
• A61L 27/24 - Collagen
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/38 - Animal cells
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/56 - Porous or cellular materials
• A61L 27/58 - Materials at least partially resorbable by the body
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

This automatic conveyance system is provided with a plurality of conveyance devices and a management device that manages the plurality of conveyance devices. The management device is capable of executing: a task assignment process for assigning a task to each of the conveyance devices; and a task optimization process for switching conveyance tasks when a conveyance cost is calculated for the case in which assigned conveyance tasks are switched between two of the conveyance devices different from each other and if the calculated conveyance cost is less than a conveyance cost at the time of the task assignment process, or when a conveyance cost is calculated for the case in which the assigned conveyance tasks and unassigned conveyance tasks are switched and if the calculated conveyance cost is less than a conveyance cost in which the unassigned conveyance tasks are assigned to any of the conveyance devices. The management device executes the task optimization process while the conveyance devices processes the tasks assigned by the task assignment process.

IPC Classes  ?

• B65G 1/00 - Storing articles, individually or in orderly arrangement, in warehouses or magazines
• B65G 1/137 - Storage devices mechanical with arrangements or automatic control means for selecting which articles are to be removed

Abstract

Disclosed is a combination vaccine for the prevention of influenza and new coronavirus infections. As a combination vaccine for vaccination against influenza and new coronaviruses, an inactivated whole virus particle vaccine, in which viral particles of an influenza virus and viral particles of a new coronavirus are inactivated respectively, is prepared. This vaccine induces neutralizing antibodies against the respective viruses without affecting vaccine effects so that protective effects against the attacks of the respective viruses are obtained. Further, the combination vaccine having this combination well induces neutralizing antibodies and exhibits protective effects against the attacks of the viruses even without adding an adjuvant.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 37/04 - Immunostimulants

Abstract

The present invention provides a composition for inducing immune tolerance, the composition containing: pluripotent stem cells that have the ability to form teratoma cells; or teratoma cells derived from the pluripotent stem cells. The present invention also provides a method for inducing immune tolerance in a mammalian individual, the method including administering an effective amount of the pluripotent stem cells or the teratoma cells to a mammal individual for which immune tolerance is desired. By inducing immune tolerance in a mammalian individual by an immune-tolerance-inducing composition and an immune tolerance inducer, autoimmune diseases can be treated and allogeneic transplantation can be performed under a condition in which a reduced amount of an immunosuppressant is used compared to the amount conventionally used, or under a condition in which no immunosuppressant is used.

IPC Classes  ?

• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 5/09 - Tumour cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells

Abstract

Provided is a microbial nucleic acid detection method, etc., that permits fast, easy, and highly accurate measurement of the concentration of a target nucleic acid and can also ensure an adequate measurement range (dynamic range). The microbial nucleic acid detection method comprises: a step in which a probe solution, which is a solution of a gold nanoparticle probe in which DNA that binds specifically to the target nucleic acid is modified with gold nanoparticles, is mixed with an extract obtained by subjecting a sample to nucleic acid extraction treatment, sodium chloride, at least, is also added and the mixture is heated to prepare a sample mixed solution; a step in which an absorption spectrum of the probe solution is acquired; a step in which an absorption spectrum of a blank solution is acquired, the blank solution being is a sample-free solution obtained by adding sodium chloride to the probe solution and heating; a step in which an absorption spectrum of the sample mixed solution is acquired; and a calculation step in which the concentration of the target nucleic acid in the sample is estimated based on the absorption spectra of the probe solution, the blank solution, and the sample mixed solution.

IPC Classes  ?

• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

HAlHAlAl of the mass ratio of aluminum atoms in the range from the surface of the protective film (3) to a position at a depth of 1 μm is 0.2-0.7.

IPC Classes  ?

• C25D 11/18 - After-treatment, e.g. pore-sealing

Abstract

The present invention enables highly accurate markerless tracking of tumor movement on the basis of a real-time image. A movement tracking device that tracks the movement of a target and a tissue in a specific region is provided, comprising: a movement estimating unit that acquires an estimated 3D motion which is obtained by estimating a three-dimensional movement of the target and the tissue on a real-time basis, and an estimated 2D motion which is obtained by estimating a two-dimensional movement of the target and the tissue on a real-time basis; an image acquisition unit that acquires a reference 2D image which is a two-dimensional image of the specific region at a predetermined reference time and a real-time 2D image which is a two-dimensional image of the specific region at real time; an image simulator that uses the estimated 2D motion and the reference 2D image to generate a pseudo real-time 2D image that simulates the two-dimensional image of the specific region at real time; and an estimation correction unit that corrects the estimated 3D motion on the basis of a comparison between the pseudo real-time 2D image and the real-time 2D image.

IPC Classes  ?

• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

6486488O including slightly oxidized copper-coated copper particles being slightly oxidized copper particles having an average particle diameter of 1 nm to 20 nm inclusive and a medium, wherein the content of the slightly oxidized copper-coated copper particles is greater than 85 mass %.

IPC Classes  ?

• C09J 1/00 - Adhesives based on inorganic constituents
• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• B22F 1/05 - Metallic powder characterised by the size or surface area of the particles
• B22F 1/14 - Treatment of metallic powder
• B22F 7/08 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite workpieces or articles from parts, e.g. to form tipped tools with one or more parts not made from powder
• H01B 1/22 - Conductive material dispersed in non-conductive organic material the conductive material comprising metals or alloys

Abstract

The present invention addresses the problem of providing: (i) a reduction method for reducing a substrate, which is composed of one or more compounds each having an unsaturated bond, by means of a mechanochemical treatment using at least a proton source and a metal including one or more elements selected from among alkali metals and alkaline earth metals; and (ii) a reduction method which enables the achievement of a reaction product that is similar to the reaction product by Birch reduction, with which the reaction can be carried out under mild temperature conditions in the ambient atmosphere without using liquid ammonia and high activity in the reduction reaction can be exhibited without using any solvent or substantially without using an organic solvent, and which enables the achievement of a reaction product with a high yield within a short time by a simple operation and is applicable to a wide range of substrates. The present invention provides, as a means for solving the problem, a reduction method for reducing a substrate (A) by a mechanochemical treatment using at least a metal (B) and a proton source (C), wherein: the substrate (A) is composed of one or more compounds each having an unsaturated bond; and the metal (B) includes one or more elements that are selected from among alkali metals and alkaline earth metals.

IPC Classes  ?

• C07C 5/11 - Partial hydrogenation
• C07B 31/00 - Reduction in general
• C07B 35/02 - Reduction
• C07C 5/05 - Partial hydrogenation
• C07C 13/23 - Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a six-membered ring with a cyclohexadiene ring
• C07C 13/48 - Completely or partially hydrogenated naphthalenes
• C07C 13/58 - Completely or partially hydrogenated anthracenes
• C07C 13/547 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings at least one ring not being six-membered, the other rings being at the most six-membered
• C07C 15/18 - Polycyclic non-condensed hydrocarbons containing at least one group with formula
• C07C 29/19 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrogenation of carbon-to-carbon double or triple bonds in six-membered aromatic rings
• C07C 33/14 - Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
• C07C 41/20 - Preparation of ethers by reactions not forming ether-oxygen bonds by hydrogenation of carbon-to-carbon double or triple bonds
• C07C 43/303 - Compounds having groups having acetal carbon atoms bound to acyclic carbon atoms
• C07C 51/36 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by hydrogenation of carbon-to-carbon unsaturated bonds
• C07C 57/26 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
• C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
• C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 269/04 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
• C07C 271/12 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals

Abstract

Provided is a reaction heat utilization system capable of enhancing temperature controllability in a reactor and utilizing reaction heat generated in the reactor with higher efficiency. This reaction heat utilization system comprises: a reactor that accommodates a heat storage unit including a plurality of latent heat storage bodies; a supply unit that supplies one of a first fluid and a second fluid to the reactor in a switchable manner; and a discharge unit that discharges generated fluid generated through a chemical reaction from the reactor. Each latent heat storage body has a core part including a latent heat storage material, and a shell part that has a melting point higher than that of the latent heat storage material and that seals the latent heat storage material therein. The first fluid includes a starting fluid that causes an exothermic reaction in the reactor and/or the second fluid includes a starting fluid that causes an endothermic reaction in the reactor. The reaction heat utilization system is configured to switch alternately between a heat storage mode in which heat is stored in the heat storage unit as a result of the first fluid being supplied from the supply unit to the reactor, and a heat radiation mode in which heat is released from the heat storage unit as a result of the second fluid being supplied from the supply unit to the reactor.

IPC Classes  ?

• F28D 20/02 - Heat storage plants or apparatus in generalRegenerative heat-exchange apparatus not covered by groups or using latent heat
• C07C 1/04 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon monoxide with hydrogen
• C07C 1/22 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only oxygen atoms as hetero atoms by reduction
• C07C 9/04 - Methane

Abstract

Disclosed is a ceramic reversible cell which contains at least one substance selected from the group consisting of perovskite type metal oxides, hydrates of the perovskite type metal oxides, and hydrides of the perovskite type metal oxides, wherein: the at least one substance selected from the group consisting of perovskite type metal oxides, hydrates of the perovskite type metal oxides, and hydrides of the perovskite type metal oxides contains A (wherein A is at least one element selected from the group consisting of Ba, Sr and Ca), B (wherein B is at least one element selected from the group consisting of Zr, Sn, Ce, Ti and Hf) and M (wherein M is at least one element selected from the group consisting of In, Fe, Cr and Mn) as main metal atoms; and hydride ions are contained therein when equilibrium is reached by bringing dried hydrogen into contact with the ceramic reversible cell, the dried hydrogen satisfying a specific formula and having a moisture content of 20 ppm or less in terms of volume ratio at 500°C to 900°C.

IPC Classes  ?

• C25B 13/07 - DiaphragmsSpacing elements characterised by the material based on inorganic materials based on ceramics
• C01G 25/02 - Oxides
• C04B 35/50 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on rare earth compounds
• C04B 35/488 - Composites
• C25B 1/042 - Hydrogen or oxygen by electrolysis of water by electrolysis of steam
• C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
• C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
• C25B 13/04 - DiaphragmsSpacing elements characterised by the material
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte
• H01M 8/1246 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte characterised by the process of manufacturing or by the material of the electrolyte the electrolyte consisting of oxides

Abstract

[Problem] To provide a screening method for candidate compounds capable of serving as a preventive or therapeutic agent for suppressing individual deaths of honeybees due to viral infection and to provide a preventive or therapeutic agent tied to suppression of honeybee mass deaths due to viral infection. [Solution] The cause of mass deaths of honeybee was identified as intestinal tract damage due to a virus-derived protease mediated by mites, and it was discovered that individual deaths and intestinal tract damage were suppressed in the virus infection group by administration of viral dsRNA. Furthermore, it was discovered that individual deaths in the virus infection group were suppressed by inhibiting the virus-derived protease by administering E-64 ([(2S,3S)-3-carboxyoxylan-2-carbonyl]-L-leucine (4-guanidinobutyl) amide hemihydrate).

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61P 31/12 - Antivirals
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase

Abstract

[Problem] To provide a metal heating furnace and a method for combusting ammonia by using a metal heating furnace, whereby it becomes possible to combust ammonia while effectively reducing nitrogen oxides. [Solution] Provided is a metal heating furnace 10 in which ammonia is combusted as a fuel with fire F from a burner nozzle 31 provided in a furnace wall 11. The metal heating furnace 10 is provided with: a plurality of ammonia injection nozzles 41, 42, 43 which are arranged at intervals in the fire F-extending direction in a ceiling wall 13 and through which ammonia is injected in a direction orthogonal to the fire F-extending direction; and a control device 100 which adjusts the amounts of ammonia to be ejected through the ammonia ejection nozzles 41, 42, 43 for every ammonia ejection nozzle 41, 42, 43.

IPC Classes  ?

• F27D 7/02 - Supplying steam, vapour, gases or liquids
• F23C 1/00 - Combustion apparatus specially adapted for combustion of two or more kinds of fuel simultaneously or alternately, at least one kind of fuel being either a fluid fuel or a solid fuel suspended in air
• F23C 99/00 - Subject matter not provided for in other groups of this subclass
• F23D 14/02 - Premix gas burners, i.e. in which gaseous fuel is mixed with combustion air upstream of the combustion zone
• F23J 7/00 - Arrangement of devices for supplying chemicals to fire
• F23K 5/00 - Feeding or distributing other fuel to combustion apparatus
• F23N 1/00 - Regulating fuel supply
• F27B 5/16 - Arrangements of air or gas supply devices
• F27B 5/18 - Arrangement of controlling, monitoring, alarm or like devices

Abstract

The present invention provides: lipid nanoparticles that are for editing mitochondrial genome and that each include an RNA-guided DNA nuclease and a guide RNA; and a dispersion containing, in a dispersion medium, said lipid nanoparticles as a dispersoid. The present invention also provides a pharmaceutical composition that contains said lipid nanoparticles and that is for preventing or treating mitochondrial diseases, particularly a pharmaceutical composition for preventing or treating MELAS. The present invention further provides methods for producing the lipid nanoparticles and the dispersion.

IPC Classes  ?

• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• A61K 9/10 - DispersionsEmulsions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/51 - Nanocapsules
• A61K 38/46 - Hydrolases (3)
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/09 - Recombinant DNA-technology

Abstract

A water electrolysis electrode for use in a water electrolysis device in which a hydrogen-producing reaction electrode and an oxygen-producing reaction electrode are brought into contact with water and a voltage is applied between both electrodes to produce hydrogen and oxygen, said water electrolysis electrode having, on at least a portion of a surface thereof, one or more structures selected from the group consisting of a plurality of nanostructures and a plurality of microstructures which, during water electrolysis, interact with at least one type of polarization selected from the group consisting of electronic polarization of a chemical reaction intermediate during water electrolysis and vibrational polarization of water molecules.

IPC Classes  ?

• C25B 11/02 - ElectrodesManufacture thereof not otherwise provided for characterised by shape or form
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
• C25B 11/04 - ElectrodesManufacture thereof not otherwise provided for characterised by the material

Abstract

Provided is a magnetic core in which power feeding efficiency and robustness against position error are increased. A magnetic core of the present disclosure comprises: a base portion; a column portion extending upward from the base portion; a cap portion connected to the column portion; and a wall portion extending upward from the base portion and provided to surround the column portion in plan view. The cap portion opposes the base portion in the vertical direction, and extends outside the column portion in plan view. The cap portion is smaller than the base portion in plan view, and is positioned inside the outer edge of the wall portion. The upper end of the wall portion is positioned lower than the upper surface of the cap portion.

IPC Classes  ?

• H01F 27/24 - Magnetic cores
• H01F 38/14 - Inductive couplings
• H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
• H02J 50/90 - Circuit arrangements or systems for wireless supply or distribution of electric power involving detection or optimisation of position, e.g. alignment

Abstract

This life design proposal system comprises a computer having a calculation device that executes a predetermined calculation process, and a storage device connected to the calculation device, wherein the calculation device includes a reception unit that receives a life plan desired by a user and a balance of well-being desired by the user; an extraction unit that extracts a subject that matches the received life plan; and an output unit that outputs data on a plurality of role models including the age at which a life event occurred and well-being at the time of each life event, on the basis of the satisfaction level of the extracted subject in the life events.

IPC Classes  ?

• G06Q 50/10 - Services

Abstract

This forceps system comprises: a tubular guide sheath (2); a forceps (3) that has an openable and closable gripping section (7), and is inserted into the guide sheath (2) in the longitudinal direction of the guide sheath (2); and an orientation adjustment mechanism (8, 9) that is provided in the guide sheath (2) and the forceps (3), and adjusts the orientation of the gripping section (7) relative to the guide sheath (2). The guide sheath (2) has a shielding section (4) provided in a circumferential portion of a tip end part of the guide sheath (2). The orientation adjustment mechanism (8, 9) adjusts the gripping section (7) disposed at the tip end part of the guide sheath (2) to a predetermined orientation where the openable and closable side of the gripping section (7) faces away from the shielding section (4).

IPC Classes  ?

• A61B 17/29 - Forceps for use in minimally invasive surgery
• A61B 10/06 - Biopsy forceps

Abstract

[Problem] To provide an industrial furnace that can combust ammonia effectively and facilitate reduction in nitrogen oxides. [Solution] An industrial furnace 1 uses flame F from a burner 10 to combust ammonia which is supplied along with combustion air and fuel gas to the burner 10. Tips of tube-shaped ammonia injection nozzles 21, 22, 23, 24, which are arranged in communication with the wall surface of a furnace body 2 in the furnace 1 and which are provided so as to inject only ammonia, are protruded inward to the furnace body 2 from the wall surface. The entirety of the ammonia injection nozzles 21, 22, 23, 24 are formed by using a catalyst C which decomposes ammonia into hydrogen and nitrogen.

IPC Classes  ?

• F23K 5/00 - Feeding or distributing other fuel to combustion apparatus
• F23C 1/00 - Combustion apparatus specially adapted for combustion of two or more kinds of fuel simultaneously or alternately, at least one kind of fuel being either a fluid fuel or a solid fuel suspended in air
• F23C 13/08 - Apparatus in which combustion takes place in the presence of catalytic material characterised by the catalytic material
• F23K 5/08 - Preparation of fuel
• F23K 5/10 - Mixing with other fluids

Abstract

The present invention relates to manganese dioxide suitable as a raw material of an electrode material for a polyvalent metal ion secondary battery. The manganese dioxide according to the present invention has an α-type crystal structure. Ammonium ions are incorporated in the α-type crystal structure. The manganese dioxide according to the present invention has an average crystallite size of at most 5.0 nm, as measured using the Scherrer method based on X-ray diffraction, and a BET specific surface area of at least 100 m2/g.

IPC Classes  ?

• C01G 45/02 - Oxides
• H01M 4/48 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium

Abstract

A solid material sustainedly releasing ethylene gas, the solid material comprising a silver-containing zeolite and a dehydrating agent, wherein a layer comprising the silver-containing zeolite and a layer comprising the dehydrating agent are preferably arranged so that the ethylene gas released from the silver-containing zeolite passes through the layer comprising the dehydrating agent.

IPC Classes  ?

• C09K 3/00 - Materials not provided for elsewhere
• A23B 7/152 - Preserving or ripening with chemicals not covered by group or in the form of gases, e.g. fumigationCompositions or apparatus therefor in a controlled atmosphere comprising other gases in addition to CO2, N2, O2 or H2O
• A23L 19/12 - Products from fruits or vegetablesPreparation or treatment thereof of tuberous or like starch containing root crops of potatoes
• C01B 39/14 - Type A
• C01B 39/22 - Type X

Abstract

The present invention relates to manganese dioxide suitable as a raw material of an electrode material for a polyvalent metal ion secondary battery. The manganese dioxide according to the present invention has an α-type crystal structure. Ammonium ions are incorporated in the α-type crystal structure. The manganese dioxide according to the present invention has an average crystallite size of at most 5.0 nm, as measured using the Halder-Wagner method based on X-ray diffraction, and a BET specific surface area of at least 100 m2/g.

IPC Classes  ?

• C01G 45/02 - Oxides
• H01M 4/48 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium

Abstract

Provided are a diagnosis method and a testing method for muscular dystrophy in cats. The diagnosis method is for determining whether a cat under examination has developed muscular dystrophy, wherein information about the dystrophin gene of the cat under examination is acquired from a biological sample collected from the cat under examination, and on the basis of the information, it is determined whether the cat under examination has developed muscular dystrophy. Further, the testing method is for determining whether a cat under examination or a descendant thereof has a risk of developing muscular dystrophy, wherein information about the dystrophin gene of the cat under examination is acquired from a biological sample collected from the cat under examination, and on the basis of the information, it is determined whether the cat under examination or a descendant thereof has a risk of developing muscular dystrophy.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A01K 67/02 - Breeding vertebrates
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a method for comprehensively detecting autoantigens of an immune-mediated disease in a short period of time. A method for detecting autoantigens of an immune-mediated disease according to the present invention comprises: a step for bringing antibodies obtained from an immune-mediated-disease sample, and a lysate of animal tissue, into contact with each other; a step for eluting proteins that are bonded to the antibodies; and a step for performing mass spectrometry of the eluted proteins without performing electrophoresis.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The purpose of the present disclosure is to provide a pharmaceutical composition having an excellent therapeutic effect on the treatment of central nervous system diseases.　A pharmaceutical composition for transnasal administration to be used for treating central nervous system diseases and containing a purified product of extracellular vesicles, in which the purified product of extracellular vesicles is obtained by a method for producing a purified product of extracellular vesicles, the method comprising: (i) a purification step in which a solution to be treated containing extracellular vesicles and foreign substances is brought into contact with an exclusive anion exchange carrier to obtain a treated solution containing the extracellular vesicles; and (ii) a membrane filtration step in which the treated solution is subjected to membrane filtration to obtain a concentrated solution of the extracellular vesicles. The pharmaceutical composition for transnasal administration has an excellent therapeutic effect on the treatment of central nervous system diseases.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• B01D 61/14 - UltrafiltrationMicrofiltration
• B01D 61/16 - Feed pretreatment
• B01D 61/22 - Controlling or regulating
• B01D 63/02 - Hollow fibre modules
• B01J 41/10 - Inorganic material
• B01J 41/13 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 41/14 - Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds
• B01J 41/16 - Cellulose or woodDerivatives thereof
• B01J 41/18 - Carbon, coal or tar
• B01J 41/20 - Anion exchangers for chromatographic processes

Abstract

The problem addressed is: to provide a polymer mechanoradical initiator obtained by mechanochemical treatment of an organic polymer material as a radical initiator for reactions in which the polymer mechanoradical initiator component is not incorporated into the reaction product; to provide a reaction method for radical reduction of an organic halogen compound using a polymer mechanoradical initiator obtained by mechanochemical treatment of an organic polymer material; to provide a reaction method for radical cyclization of an organic halogen compound using a polymer mechanoradical initiator obtained by mechanochemical treatment of an organic polymer material; or to provide a reaction method for C-H fluorination of a compound having a C-H bond based on a secondary carbon or a tertiary carbon using a polymer mechanoradical initiator obtained by mechanochemical treatment of an organic polymer material. Provided as a solution are: (i) a polymer mechanoradical initiator obtained by mechanochemical treatment of an organic polymer material, wherein the polymer mechanoradical initiator is used in reactions in which the polymer mechanoradical initiator is not incorporated into the reaction product; (ii) a reaction method for radical reduction and/or radical cyclization of a substrate using a polymer mechanoradical initiator, wherein the reaction method includes a step that performs mechanochemical treatment of at least an organic polymer material and a substrate inside a reactor and the substrate contains an organic halogen compound; and (iii) a reaction method for C-H fluorination of a substrate using a polymer mechanoradical initiator, wherein the reaction method includes a step that performs mechanochemical treatment of at least an organic polymer material, a substrate, and a fluorination reagent inside a reactor and the substrate contains a compound having a C-H bond based on a secondary carbon or a tertiary carbon.

IPC Classes  ?

• C07B 61/00 - Other general methods
• C07B 31/00 - Reduction in general
• C07C 5/00 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms
• C07C 9/15 - Straight-chain hydrocarbons
• C07C 13/567 - FluorenesCompletely or partially hydrogenated fluorenes
• C07C 13/615 - Adamantanes
• C07C 15/14 - Polycyclic non-condensed hydrocarbons all phenyl groups being directly linked
• C07C 15/24 - Polycyclic condensed hydrocarbons containing two rings
• C07C 15/30 - Phenanthrenes
• C07C 17/23 - Preparation of halogenated hydrocarbons by dehalogenation
• C07C 23/02 - Monocyclic halogenated hydrocarbons
• C07C 25/18 - Polycyclic aromatic halogenated hydrocarbons
• C07C 45/65 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by splitting-off hydrogen atoms or functional groupsPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by hydrogenolysis of functional groups
• C07C 49/78 - Acetophenone
• C07C 209/74 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by halogenation, hydrohalogenation, dehalogenation, or dehydrohalogenation
• C07C 211/54 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
• C07D 209/30 - IndolesHydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
• C07D 209/82 - CarbazolesHydrogenated carbazoles
• C07D 307/06 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
• C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 309/10 - Oxygen atoms
• C07D 333/76 - Dibenzothiophenes

Abstract

[Problem] To provide an industrial furnace which burns ammonia effectively while achieving a reduction in nitrogen oxides, without a particular increase in cost. [Solution] In an industrial furnace 100 equipped with a regenerative burner comprising a pair of burners 10, 20: air nozzles 11, 21 for discharging combustion air into the furnace are provided in furnace walls 101, 102 in positions at the centers of the burners 10, 20; fuel nozzles 12, 22 for discharging a fossil fuel into the furnace are provided on one of two sides sandwiching the air nozzles 11, 21, and ammonia nozzles 13, 23 for discharging ammonia into the furnace are provided on the other side; and the ammonia is burned using the burners 10, 20.

IPC Classes  ?

• F23D 14/22 - Non-premix gas burners, i.e. in which gaseous fuel is mixed with combustion air on arrival at the combustion zone with separate air and gas feed ducts, e.g. with ducts running parallel or crossing each other
• F23C 1/00 - Combustion apparatus specially adapted for combustion of two or more kinds of fuel simultaneously or alternately, at least one kind of fuel being either a fluid fuel or a solid fuel suspended in air
• F23D 14/84 - Flame spreading or otherwise shaping
• F23L 15/00 - Heating of air supplied for combustion
• F23L 15/02 - Arrangements of regenerators
• F27D 7/02 - Supplying steam, vapour, gases or liquids

Abstract

The present invention addresses the problem of providing a method for producing a homo-coupling reaction product, whereby it becomes possible to substantially eliminate the use of an organic solvent, to carry out a reaction under a mild reaction condition by a simple reaction operation, to use a broad range of organic halogen compounds as starting materials, to produce a reaction product within a short time with high yield, and to produce a reaction product having a higher molecular weight. As a solution for the problem, a method for producing a homo-coupling reaction product of an organic halogen compound represented by formula (I): A1mm (wherein A1 represents any one of an m-valent aromatic hydrocarbon group which may have a substituent, an m-valent aromatic heterocyclic group which may have a substituent, an m-valent heterocyclic group which may have a substituent, an m-valent aliphatic hydrocarbon group which may have a substituent, and an m-valent unsaturated aliphatic hydrocarbon group which may have a substituent; X represents any one of a chlorine atom, a bromine atom and an iodine atom, in which, when there are a plurality of X's, the X's may be the same as or different from each other; and m represents the number of X's and is an integer of 1 or more) is provided, in which the organic halogen compound represented by formula (I) is reacted by a mechano-chemical method in the presence of a nickel catalyst under the following condition (a) and/or the following condition (b). Condition (a): the amount of a solvent to be used is 0.8 mL or less relative to 1 mmol of the organic halogen compound. Condition (b): a hetero-atom-containing compound is present.

IPC Classes  ?

• C07B 37/04 - Substitution
• C07B 61/00 - Other general methods
• C07C 1/26 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only halogen atoms as hetero atoms
• C07C 15/14 - Polycyclic non-condensed hydrocarbons all phenyl groups being directly linked
• C07C 15/38 - Polycyclic condensed hydrocarbons containing four rings
• C07C 15/52 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part substituted by unsaturated hydrocarbon radicals polycyclic non-condensed containing a group with formula
• C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
• C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
• C07C 45/68 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by isomerisationPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by change of size of the carbon skeleton by increase in the number of carbon atoms
• C07C 49/784 - Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with all keto groups bound to a non-condensed ring
• C07C 67/343 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisationPreparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by change of size of the carbon skeleton by increase in the number of carbon atoms
• C07C 69/76 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring
• C07C 209/68 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
• C07C 211/54 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
• C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
• C07C 255/51 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings containing at least two cyano groups bound to the carbon skeleton
• C07D 209/82 - CarbazolesHydrogenated carbazoles
• C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07D 333/52 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes
• C07D 333/76 - Dibenzothiophenes
• C07F 5/04 - Esters of boric acids
• C08G 61/00 - Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule

Abstract

Provided are: a sulfide solid electrolyte production method which provides, at a high production efficiency, a sulfide solid electrolyte that contains lithium atoms, phosphorus atoms, sulfur atoms, and oxygen atoms, and that has high water resistance, the method including mixing a raw-material-containing substance and a protonic organic solvent containing oxygen atoms to thereby prepare a solution; and a sulfide solid electrolyte that contains lithium atoms, phosphorus atoms, sulfur atoms, and oxygen atoms, and that has a prescribed diffraction peak in an X-ray diffraction measurement using a CuKα ray.

IPC Classes  ?

• H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
• C01B 25/14 - Sulfur, selenium, or tellurium compounds of phosphorus
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances
• H01B 1/10 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances sulfides
• H01M 10/052 - Li-accumulators
• H01M 10/0562 - Solid materials

Abstract

This prediction device comprises an operational circuit, a storage device, and a communication circuit. The storage device stores correlation information showing correlations between temporal changes in the intensity of each typhoon of a plurality of typhoons and temporal changes in index values of lightning discharges that occurred in the area of influence of each typhoon. The correlation information includes time differences between the time at which the index values of lightning discharges reached a maximum and the times at which the intensity of each typhoon reached a maximum within the period of time from the outbreak of the typhoon to the extinction of the typhoon. The operational circuit acquires lightning data including the position and time of the occurrence of lightning discharges observed during a prescribed period of time, acquires typhoon data including the center position and intensity of an observed typhoon, calculates, on the basis of the lightning data, an index value of lightning discharges that occurred within a prescribed range from the center position, generates lightning discharge information indicating the temporal change in the calculated index value, and calculates a predicted value of the intensity of the typhoon on the basis of the correlation information, lightning discharge information, and the intensity of the typhoon at the latest observation time in the typhoon data.

IPC Classes  ?

• G01W 1/10 - Devices for predicting weather conditions

Abstract

Provided is a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition containing a retinoic acid receptor (RAR) agonist.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/203 - Retinoic acids
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/09 - Recombinant DNA-technology

Abstract

This protein manufacturing method comprises a manufacturing step for causing a plant, having introduced therein a nucleic acid fragment encoding a target protein, to produce the target protein. The plant has the autophagy system thereof suppressed. The plant may be a plant in which the function of autophagy-related genes is suppressed or deficient, or a plant in which the expression of the autophagy-related genes is suppressed or lost. The autophagy-related genes preferably include at least one gene selected from the group consisting of ATG6 gene, ATG7 gene, ATG5 gene, and ATG8 gene.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• A01H 6/82 - Solanaceae, e.g. pepper, tobacco, potato, tomato or eggplant
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

Provided is a novel anti-influenza virus agent which inhibits the growth and infection mechanisms of influenza virus and thus has a target other than specific viral proteins and which does not cause the emergence of drug-resistant viruses. Also provided are a medicine, food, beverage, supplement, agricultural chemical, feed and cosmetic using the same. An anti-influenza virus composition containing, as an active ingredient, tubercidin, a tubercidin derivative or a salt thereof, and a medicine, food, beverage, supplement, agricultural chemical, feed and cosmetic using the same.

IPC Classes  ?

• A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A23K 20/163 - SugarsPolysaccharides
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/69 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

This suction device is attached to a bottomed cylindrical container. The suction device comprises a suction part, a suction machine, a suction tube, and a filter. The suction part has a suction port and is attached to an opening of the container. The suction machine suctions air. The suction tube is connected to the suction part and the suction machine and communicates with the suction port, and air circulates through the suction tube. The filter is connected to the suction tube.

IPC Classes  ?

• H01J 37/20 - Means for supporting or positioning the object or the materialMeans for adjusting diaphragms or lenses associated with the support

Abstract

Provided are: a nucleic acid complex composition that has high efficiency for introducing nucleic acid molecules into cells and for diffusing the same within the cells and that can have high transfection efficiency; lipid particles for transfection; and a transfection method using the same. The present invention pertains to a nucleic acid complex composition, lipid particles for transfection, and a transfection method using the same. The nucleic acid complex composition contains nucleic acid molecules and a polycation having a structure formed through polymerization of cation molecules comprising a molecule chain including carbon atoms and nitrogen atoms.

IPC Classes  ?

• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• C07K 19/00 - Hybrid peptides

Abstract

A control unit of this ocular fundus image processing device executes an ocular fundus image acquisition step, a blood vessel image acquisition step, and a probability map generation step. In the ocular fundus image acquisition step, the control unit acquires a plurality of ocular fundus images each including a blood vessel in the ocular fundus in an eye to be examined, which are captured by an ocular fundus image capture device. In the blood vessel image acquisition step, the control unit acquires a blood vessel image which shows at least one of an artery and a vein contained in each of the acquired ocular fundus images. In the probability map generation step, the control unit adds a plurality of blood vessel images respectively acquired for the plurality of ocular fundus images in an aligned state to generate a retinal blood vessel distribution probability map showing the distribution of existence probability of blood vessels present in the retina of the eye.

IPC Classes  ?

• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
• A61B 3/14 - Arrangements specially adapted for eye photography
• G16H 30/00 - ICT specially adapted for the handling or processing of medical images
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

The present invention provides: a conception chance-improving composition for normalization of EGF concentration profile and conception chance improvement for a ruminant; and a method for improving ruminant conception chance using said composition. The present invention is: a ruminant conception chance-improving composition comprising, as an active ingredient, a peptide or polypeptide including the amino acid sequence represented by SEQ ID NO: 1; a ruminant conception chance-improving composition having, as an active ingredient, bovine osteopontin protein, a mutant of bovine osteopontin protein, or a partial peptide of these proteins, in which the protein, the mutant, and the partial peptide include the amino acid sequence represented by SEQ ID NO: 1; and a method for improving ruminant conception chance in which either of the conception chance-improving compositions is administered to the fornix vaginae, or the vicinity thereof, of the vaginal portion of a ruminant on an estrous day or the period immediately before/after such.

IPC Classes  ?

• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

Provided is a feature for accurately irradiating a tumor with radiation. This motion tracking device has: a medical image extraction device for extracting, from a medical image of a patient, motion information which is information pertaining to the motion in a specific region of a target, tissue around the target, and a surrogate which is a pathognomic site; a motion model generator which constructs a motion model expressing the correlation between the motion of the target, the tissue and the surrogate on the basis of the motion information; a motion detector for measuring the motion of the surrogate during a treatment for irradiating the patient with therapeutic radiation; a motion estimator for estimating the current or future location of the target and tissue on the basis of the motion model and the motion of the surrogate; and a motion model corrector for correcting the estimated target and tissue location during treatment according to a pre-set correction protocol. The treatment control device subjects the patient to targeted therapeutic radiation on the basis of the estimated current or future location of the target and tissue.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

Provided is a diagnostic antibody that is capable of detecting PD-L1 in tumors for novel therapies for feline tumors targeting PD-1/PD-L1.　The anti-PD-L1 antibody contains: (a) an L-chain having CDR1 that has the amino acid sequence ESVDSYGNSF (SEQ ID NO: 1), CDR2 that has the amino acid sequence RAS, and CDR3 that has the amino acid sequence QQSNEDPRT (SEQ ID NO: 2); and (b) an H-chain having CDR1 that has the amino acid sequence GFTFSSYG (SEQ ID NO: 3), CDR2 that has the amino acid sequence ISNGGTYT (SEQ ID NO: 4), and CDR3 that has the amino acid sequence ARLGYGSLNWYFDV (SEQ ID NO: 5). A composition for detecting PD-L1 that contains the anti-PD-L1 antibody as an active ingredient. Also provided is a method for producing the anti-PD-L1 antibody.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/08 - Monoclonal antibodies
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

64822O; and mixing the raw material particle with a solution containing an amine-based compound and a complex forming agent, and then adding a reductant to the resultant to allow a reaction in an oxygen-containing atmosphere.

IPC Classes  ?

• B22F 1/14 - Treatment of metallic powder
• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• B22F 1/16 - Metallic particles coated with a non-metal
• B22F 7/08 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite workpieces or articles from parts, e.g. to form tipped tools with one or more parts not made from powder

Abstract

Disclosed herein include methods, compositions, and kits suitable for use in enhancing adoptive T cell therapy. In some embodiments, the method comprises contacting isolated organelle complexes with a population of T cells to generate a population of T cells comprising the organelle complexes. The organelle complexes can comprise mitochondria and one or more of endoplasmic reticulum, peroxisomes, lysosomes, and Golgi apparatus. The population of T cells can exhibit one or more of enhanced expansion capability, enhanced cytotoxicity against target cells, enhanced resistance to exhaustion, and enhanced persistence, as compared to a population of T cells that do not comprise exogenous organelle complexes

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/16 - Animal cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to lipid nanoparticles capable of delivering a target substance to hepatic stellate cells. The lipid nanoparticles are for delivering a target substance to hepatic stellate cells and comprise a pH-sensitive cationic lipid including a hydrophilic portion and two hydrophobic portions, wherein an acid dissociation constant pKa of a lipid membrane constituting the lipid nanoparticles is greater than or equal to 6.7 and less than 8.2.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

[Problem] To provide a means for mass-producing female sturgeons in a simple, inexpensive, and efficient manner.　[Solution] Provided is a sturgeon breeding method comprising causing a solid feed, in which a soybean isoflavone-containing substance containing genistein is almost uniformly mixed, to be ingested. Almost all individuals among cultured individuals that are genetically approximately half males and half females can be bred as individuals that are female or induced to become female, by causing the solid feed to be ingested over the period of 2-10 months from the 14th-120th day after hatching, and thus female sturgeons (genetically female individuals and individuals in which genetic males are induced to become female) with high utility value for caviar production can be efficiently produced.

IPC Classes  ?

• A01K 61/10 - Culture of aquatic animals of fish
• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A23K 20/121 - Heterocyclic compounds containing oxygen or sulfur as hetero atom
• A23K 50/80 - Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs

Abstract

The present invention provides: a neutral lipid capable of suppressing the phase transition of endosomal membranes caused by phosphatidylcholine from being inhibited; and a lipid nanoparticle containing said neutral lipid. The present invention pertains to an ionic neutral lipid comprising a compound represented by general formula (I). [In formula (I), R1is a C1-22 hydrocarbon group; three R1's in one molecule may be the same group or different groups; a1 and a2 are each independently an integer of 0 to 4; b1 and b2 are 0 or 1, satisfying b1+b2=1; R2and R3 are each independently a hydrogen atom or a C1-3 alkyl group; and R4 is an anionic group.]

IPC Classes  ?

• C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C11B 11/00 - Recovery or refining of other fatty substances, e.g. lanolin or waxes

Abstract

The present invention addresses the problem of providing, without using relatively expensive starting materials, a more conveniently synthesizable pH-sensitive cationic lipid, and providing a lipid nanoparticle that contains this pH-sensitive cationic lipid. The present invention is a pH-sensitive cationic lipid represented by general formula (I) [R1is a C1-22 hydrocarbon group; the three R1's in each molecule may be the same group as each other or may be groups that differ from each other; Z1is a C1-6 alkylene group or a single bond; X is -N(R2)(R3) or is a 5- to 7-membered nonaromatic heterocyclic group (with the proviso that this group is bonded to Z1by a carbon atom); and R2and R3are each independently a hydrogen atom or a C1-4 hydrocarbon group, but R2and R3 may be bonded to each other with the formation of a 5- to 7-membered nonaromatic heterocycle].

IPC Classes  ?

• C07C 237/08 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
• A61K 9/51 - Nanocapsules
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present invention improves prediction accuracy when predicting a process state on the basis of time series sensor data. This reservoir device accepts input of time-series sensor data measured in a predetermined process, and outputs a reservoir feature quantity on the basis of results from processing performed using an input weight multiplication unit and a connection weight multiplication unit. The input weight multiplication unit weights the input sensor data using a value determined by a periodic function as the input weight. The connection weight multiplication unit weights and adds data indicating the state of each node, using a value determined by a periodic function as the node-to-node connection weight.

IPC Classes  ?

• G06N 3/044 - Recurrent networks, e.g. Hopfield networks
• G06N 3/063 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means

Abstract

SFlFl) of the transport path (capillary C) is greater than 0° and less than 180°.

IPC Classes  ?

• G02B 21/00 - Microscopes
• G01N 21/05 - Flow-through cuvettes
• G01N 21/64 - FluorescencePhosphorescence
• G02B 21/06 - Means for illuminating specimen
• G02B 21/26 - StagesAdjusting means therefor
• G02B 21/34 - Microscope slides, e.g. mounting specimens on microscope slides

Abstract

This image processing system (100) includes a memory (120) for storing a learned model (130) and a processor (110). The processor (110) acquires a plurality of estimation results by inputting a plurality of endoscopic images associated with a single case into the learned model (130). Position information associated with the position of a digestive tract is added to each of the endoscopic images. The processor (110) tallies a plurality of estimation results using the obtained plurality of estimation results and the position information, and integrates the plurality of estimation results on the basis of the result of the tally, thereby determining the state of infection by Helicobacter pylori bacterium with respect to the individual cases.

IPC Classes  ?

• A61B 1/045 - Control thereof

Abstract

Provided is a treatment method that provides a better response rate and/or life-extending effectiveness in nonhuman mammals with cancer.　Provided are: a method for treating cancer in non-human mammals, the method comprising starting treatment with a PD-1/PD-L1 inhibitor after radiation therapy; a drug composition for treating cancer in non-human mammals, wherein the composition comprises a PD-1/PD-L1 inhibitor and administration of the composition is begun after radiation therapy; and a PD-1/PD-L1 inhibitor for use in a method for treating cancer in nonhuman mammals, wherein the method comprises starting treatment with a PD-1/PD-L1 inhibitor after radiation therapy.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 35/00 - Antineoplastic agents
• A61P 35/02 - Antineoplastic agents specific for leukemia
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The purpose of the present invention is to provide a method for producing an aromatic compound, wherein a cross-coupling reaction by means of a mechanochemical process is carried out in a state where a solvent is not substantially contained, the method being able to be applied to a wide range of base materials.　A method for producing an aromatic compound according to the present invention performs a cross-coupling reaction of an aromatic compound (A) that has a leaving group and a compound (B) that can be cross-coupled in the presence of a palladium catalyst (C) and a base (D) in a state where a solvent is not substantially contained. This method for producing an aromatic compound comprises: a step in which a solution of the palladium catalyst (C) is prepared; and a step in which a cross-coupling reaction is carried out by adding and mixing the solution of the palladium catalyst (C) to and with a mixture that contains the aromatic compound (A) that has a leaving group, the compound (B) that can be cross-coupled, and the base (D).

IPC Classes  ?

• C07C 17/269 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of only halogenated hydrocarbons
• C07B 61/00 - Other general methods
• C07C 22/08 - Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
• C07C 25/18 - Polycyclic aromatic halogenated hydrocarbons
• C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
• C07C 43/20 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
• C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
• C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
• C07C 255/50 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
• C07D 295/096 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Abstract

Disclosed herein are patches, methods, devices, and systems for delivering a non-aggregating peptide, such as alcadein and its fragments, into a subject. In some aspects, the patch includes a backing, a matrix comprising a non-aggregating peptides disposed within the matrix, and a release liner. In other aspects, the method includes opening at least one channel in the subject's skin, applying the patch described herein, thereby treating a disease or disorder associated with the brain, such as Alzheimer's disease.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 18/08 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by means of electrically-heated probes
• A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
• A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
• A61F 13/02 - Adhesive bandages or dressings
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61M 5/142 - Pressure infusion, e.g. using pumps
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61N 1/04 - Electrodes
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention addresses the problem of providing an artificial cartilage implant which is changed little even when used in a living body and can be stably used over a long period of time. The artificial cartilage implant for solving the problem has: a bone implant part which includes a polymer gel and hydroxyapatite particles dispersed at least near the surface of the polymer gel; and an artificial cartilage part which includes a polymer gel, wherein, when the cross section of the polymer gel of the artificial cartilage part is observed, the hydroxyapatite particles are not dispersed in a region spanning from the surface to a depth of 1,000 μm, or the content of the hydroxyapatite particles in the region spanning from the surface to a depth of 1,000 μm is less than 0.1 wt% in the case in which the hydroxyapatite particles are dispersed in the region.

IPC Classes  ?

• A61L 27/14 - Macromolecular materials
• A61L 27/12 - Phosphorus-containing materials, e.g. apatite
• A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
• A61L 27/52 - Hydrogels or hydrocolloids

Abstract

This plasma measurement device comprises: a laser light source 20 that emits laser light LA toward plasma PL; a spectrum measurement unit 30 that receives plasma scattered light LP from the plasma PL and measures the wavelength spectrum of such light; and an arithmetic unit 40 that calculates the electron temperature and the electron density of the plasma PL on the basis of the measured wavelength spectrum. The spectrum measurement unit 30 comprises a spectrometer having an incidence slit S1. The incidence slit S1 includes: two blades 31, 32 that are movable in an X direction within an XY plane perpendicular to the traveling direction of the plasma scattered light LP; and at least one blade 33 that is movable in a Y direction perpendicular to the X direction. The slit shape is configured using the edges of at least the three blades 31–33. This configuration makes it possible to perform more accurate measurements while easing structural constraints on plasma measurement.

IPC Classes  ?

• G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited

Abstract

The present invention relates to a catalyst for oxidative dehydrogenation of propane, the catalyst for oxidative dehydrogenation being obtained by having a ceria carrier support an active component, wherein: platinum element and an M1 element that is a typical metal element are contained in the active component; an M2 element that is a transition metal element may be contained in the active component; the total number of the M1 element and the M2 element contained in the active component is two or more; the M1 element is composed of one or more typical metal elements that are selected from the group consisting of tin element, gallium element, indium element, zinc element and germanium element; and the M2 element is composed of one or more transition metal elements that are selected from the group consisting of cobalt element, nickel element, iron element and copper element.

IPC Classes  ?

• B01J 23/89 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with noble metals
• C07C 5/42 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with a hydrogen acceptor
• C07C 11/06 - Propene
• C07B 61/00 - Other general methods

Abstract

Provided is a novel technique for regulating mRNA splicing. An artificial RNA molecule comprising the following (a) and (b), wherein (a) and (b) are arranged in this order from the 5'-side to the 3'- side. (a) A polynucleotide potentially having a secondary structure represented by formula (I), or a polynucleotide in which 1 to 3 bases are substituted, deleted, or added in the 7 bases on the 3'-side of a polynucleotide potentially having the secondary structure represented by formula (I). (b) An mRNA precursor-targeting polynucleotide containing a sequence complementary to a target sequence which is a partial sequence of an mRNA precursor.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

The present invention provides aminopolyester or the like having a structure represented by general formula (P-1) (in the formula, Z1is an alkylene group; one hydrogen atom in the alkylene group of Z1above may be substituted with -O-[D1]n2-H; and D1is a divalent group represented by general formula (P) (in the formula, a carbon atom in the carbonyl group is bonded to Z1above via an oxygen atom; one among R11-R13is a C1-C12 alkyl group, and the rest are hydrogen atoms; R14is a hydrogen atom or a methyl group; Z2 is a 1,4-cyclohexylene group; and n11-n13 are each independently 0 or 1); n1 is an integer of at least 1; and n2 is an integer of at least 0).

IPC Classes  ?

• C08G 63/685 - Polyesters containing atoms other than carbon, hydrogen, and oxygen containing nitrogen
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A medicine according to the present invention is for treating and/or preventing tumor expressing IL-34, and contains, as active ingredients, an estrogen receptor signal inhibitor, and a cytocidal anticancer agent or an immune checkpoint inhibitor.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The purpose of the present invention is to provide a therapy plan evaluation system that enables assistance of determination in selecting a therapy plan. A therapy plan evaluation system 1 for evaluating a therapy plan in a radiation therapy system RTS has a function of comparing a selected therapy plan with a track record of determination regarding past therapy plan adoption and provides the result of the comparison between the selected therapy plan and the track record.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

The present invention comprises: an introduction section that has a first solid-state device having a semiconductor quantum well structure, and into which a plurality of electron spin waves are introduced; a modulation section that has a second solid-state device having a semiconductor quantum well structure connected to the introduction section, and synthesizes the electron spin waves from the introduction section to generate multiple electron spin waves; and a separation section having a third solid-state device having a semiconductor quantum well structure connected to the modulation section, the multiple electron spin waves synthesized in the modulation section being introduced in the separation section, the separation section separating the plurality of electron spin waves from the multiple electron spin waves. The modulation section has the function of superposition of the plurality of electron spin waves by controlling the amplitude, phase, and polarization degrees of freedom of the electron spin waves using the permanent spin-swirling state in the crystal orientation dependence of the effective magnetic field due to spin-orbit interaction generated in the semiconductor quantum well structure.

IPC Classes  ?

• H04B 10/90 - Non-optical transmission systems, e.g. transmission systems employing non-photonic corpuscular radiation
• H04B 10/60 - Receivers

Abstract

For assessing the light intensity distribution of near-infrared light in a living body, a treatment planning system (1) comprises a computation unit (13) that computes and outputs, on the basis of calculation of the behavior of illuminated near-infrared light in the living body, a near-infrared light intensity distribution, which is the light intensity distribution of the near-infrared light in the living body. The computation unit computes the near-infrared light intensity distribution on the basis of calculation by the Monte Carlo method. At least a portion of the calculation is performed by a Graphics Processing Unit (GPU). The treatment planning system further comprises a setting unit (12) that sets a region of interest in the living body, and the computation unit is configured to compute the near-infrared light intensity distribution in the region of interest in the living body set by the setting unit.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light

Abstract

The present invention provides: a rubber composition for tires, the composition being capable of changing the tire performance in response to temperature changes; and a tire. The present invention relates to a rubber composition for tires, the composition containing a rubber component that contains at least one rubber selected from the group consisting of an isoprene rubber, a butadiene rubber and a styrene butadiene rubber, a crosslinking agent, carbon black, a plasticizer and a temperature-responsive material A that contains a metal salt and a polymer having a carboxyl group, wherein relative to 100 parts by mass of the rubber component, the content of the crosslinking agent is more than 0 part by mass but less than 10 parts by mass, the content of the carbon black is more than 0 part by mass but less than 100 parts by mass, and the content of the plasticizer is more than 5 parts by mass.

IPC Classes  ?

• C08L 21/00 - Compositions of unspecified rubbers
• C08L 33/02 - Homopolymers or copolymers of acidsMetal or ammonium salts thereof
• C08L 101/12 - Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
• C08L 101/14 - Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity the macromolecular compounds being water soluble or water swellable, e.g. aqueous gels
• C08K 3/04 - Carbon

Abstract

This design device (100) comprises: a beam generation unit (152) for repeatedly generating a plurality of new beams branching from a node at the distal end of an existing beam, while changing at least one of the beam length, number of branches, and the rotation angle around the axis of the existing beam on the basis of a preset rule, such that a large number of beams constituting a network structure of a porous structure are generated in a design space acquired by an acquisition unit (151); and a node joining unit (153) for selecting, among the large number of nodes generated by the beam generation unit (152), a plurality of nodes that are not directly connected by beams and joining the selected nodes to form a single node on the basis of a preset rule.

IPC Classes  ?

• G06F 30/10 - Geometric CAD
• A61F 2/28 - Bones
• A61L 27/10 - Ceramics or glasses
• A61L 27/14 - Macromolecular materials
• A61L 27/56 - Porous or cellular materials

Abstract

The present invention addresses the problem of providing lipid nanoparticles that are useful as a pharmaceutical composition for delivery to cancer or as an immunostimulating composition. The problem is solved by a pharmaceutical composition for delivery to cancer, an immunostimulating composition, or the like that contains: a pH sensitive cationic lipid represented by formula (I); a stereoisomer thereof; or a stereoisomer mixture. [In formula (I), a represents an integer of 3-5; b represents 0 or 1; R1and R2each independently represent a group represented by general formula (A) (in formula (A), R11and R121-151-15 alkyl group; c represents 0 or 1; v represents an integer of 4-12); X represents a group represented by general formula (B) (in formula (B), d represents an integer of 0-3; and R3and R41-42-41-42-42-4 alkenyl group may have one or two hydrogen atoms substituted with phenyl groups), but R3and R41-42-41-42-42-4 alkenyl group)].

IPC Classes  ?

• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/10 - DispersionsEmulsions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 9/51 - Nanocapsules
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

The present invention provides an animal management device, a program, and a health output method with which it is possible to more quickly ascertain changes in the health of each animal in a herd formed by a plurality of animals. An animal management device 1 comprises: an activity state information acquisition unit 13 that acquires activity state information, which indicates the respective activity states of a plurality of cows C present in a prescribed area; a representative value setting unit 14 that sets a representative value regarding the activity state information of the plurality of cows C; and a health output processing unit 15 that compares the representative value and the activity state information of one cow C, determines the health of the one cow C on the basis of the comparison result, and outputs the same.

IPC Classes  ?

• A01K 29/00 - Other apparatus for animal husbandry

Abstract

The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1and R2each independently represent a group represented by general formula (A) (wherein R11and R121-151-15 alkyl group; c represents an integer of 1 to 7: and e represents an integer of 4 to 12); and X represents a group represented by general formula (B) (wherein d represents an integer of 0 to 3; and R3and R41-42-42-4 alkenyl group, in which R3and R4may be bonded to each other to form a 5- to 7-membered nonaromatic hetero ring) or a 5- to 7-membered nonaromatic hetero ring group]. (R1)(R222)a-(O-CO)b-X (I) (R11)(R122222)d-N(R3)(R4) (B)

IPC Classes  ?

• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/51 - Nanocapsules
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07C 219/06 - Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

22 compound; and fine particles within the skeleton that comprise metal oxide fine particles or metal fine particles.

IPC Classes  ?

• B01J 29/035 - Crystalline silica polymorphs, e.g. silicalites
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst
• C01B 37/02 - Crystalline silica-polymorphs, e.g. silicalites

Abstract

The present invention makes it possible to ascertain the behavior of an animal accurately and efficiently. This animal behavior recording device 100 is provided with a processing unit 110 which acquires animal behavior information, that is, information indicating the behavior of an animal, acquires animal position information, that is, information indicating the positions where the animal is present, estimates the behavior of the animal on the basis of the animal behavior information and the animal position information, and records the behavior in time series. Acceleration data acquired from an acceleration sensor disposed on the animal and/or angular velocity data acquired from an angular velocity sensor disposed on the animal can be used as the animal behavior information, and the processing unit 110 is capable of estimating the behavior of the animal on the basis of one of the animal behavior information and the animal position information and correcting the estimated behavior by using the other information.

IPC Classes  ?

• A01K 29/00 - Other apparatus for animal husbandry

Abstract

This field effect transistor has: a substrate having a (111) plane, the substrate comprising a group IV semiconductor doped with a first electroconductivity type; a core-shell nanowire including a core nanowire connected to the (111) plane of the substrate, the core nanowire comprising a group III-V compound semiconductor doped with a second electroconductivity type different from the first electroconductivity type, and a shell layer disposed so as to cover the core nanowire, the shell layer comprising a group III-V compound semiconductor doped with the first electroconductivity type; a first electrode electrically connected to the shell layer; a second electrode electrically connected to the substrate; and a gate electrode for inducing a field at the joining interface between the substrate and the core nanowire and at the shell layer.

IPC Classes  ?

• H01L 29/78 - Field-effect transistors with field effect produced by an insulated gate
• H01L 21/28 - Manufacture of electrodes on semiconductor bodies using processes or apparatus not provided for in groups
• H01L 21/336 - Field-effect transistors with an insulated gate
• H01L 21/337 - Field-effect transistors with a PN junction gate
• H01L 21/338 - Field-effect transistors with a Schottky gate
• H01L 29/06 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions
• H01L 29/41 - Electrodes characterised by their shape, relative sizes or dispositions
• H01L 29/423 - Electrodes characterised by their shape, relative sizes or dispositions not carrying the current to be rectified, amplified or switched
• H01L 29/49 - Metal-insulator semiconductor electrodes
• H01L 29/808 - Field-effect transistors with field effect produced by a PN or other rectifying junction gate with a PN junction gate
• H01L 29/812 - Field-effect transistors with field effect produced by a PN or other rectifying junction gate with a Schottky gate

Abstract

The present invention provides an immunotolerance induction composition containing pluripotent stem cell-derived hematosis stem/precursor cells in which the Lhx2 gene is forcibly expressed or Lhx2 and HoxB4 are forcibly expressed. The present invention also provides a method for producing an immunotolerance induction composition, the method comprising differentiating pluripotent stem cells into hematosis stem/precursor cells under forced expression of Lhx2 or under forced expression of Lhx2 and HoxB4. The immunotolerance induction composition can be used for inducing immunotolerance in an allogeneic homograft having major histocompatibility antigen compatibility or not having major histocompatibility antigen compatibility.

IPC Classes  ?

• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins

Abstract

In this carbon dioxide immobilization method, a cured cement body (10) is impregnated with a carbon-dioxide-absorbing liquid containing a carbon dioxide absorbent (20) in order to support the carbon dioxide absorbent (20) on the cured cement body (10) and obtain a cured cement body (1) for carbon dioxide immobilization; and the cured cement body (1) for carbon dioxide immobilization is brought into contact with the atmosphere and the carbon dioxide contained in the atmosphere is immobilized in the cured cement body (1) for carbon dioxide immobilization.

IPC Classes  ?

• C23F 11/14 - Nitrogen-containing compounds
• C04B 28/02 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing hydraulic cements other than calcium sulfates
• C04B 41/62 - Coating or impregnating with organic materials
• B01D 53/62 - Carbon oxides
• E04G 23/02 - Repairing, e.g. filling cracksRestoringAlteringEnlarging

Abstract

Provided are a humanized antibody that bonds to an EVA1 protein derived from a human or a functional fragment thereof, an antibody-drug conjugate comprising the humanized antibody or functional fragment thereof, and a chimeric antigen receptor comprising an antibody that bonds to an EVA1 protein derived from a human or a functional fragment thereof.

IPC Classes  ?

• C12N 15/13 - Immunoglobulins
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/46 - Hybrid immunoglobulins
• C07K 19/00 - Hybrid peptides
• C12N 5/078 - Cells from blood or from the immune system
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

222222 gas, wherein the metal complex is one or more selected from a group of metal carbonyls represented by a specific chemical formula.

IPC Classes  ?

• B01D 53/02 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
• B01J 20/02 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material

Abstract

The light-emitting material contains two or more types of rare earth element ions and a linker ligand that forms coordination bonds with 2-4 rare earth element ions, and the two or more types of rare earth element ions and linker ligand form a rare earth complex. The two or more types of rare earth element ions include at least one type of rare earth element ion selected from the group consisting of Yb, Nd, Sm, Eu, Tb, Dy, Ce, Pr, Ho, Er, and Tm and at least one type of rare earth element ion selected from the group consisting of Y, La, Gd, and Lu. The linker ligand has a linker group and a substituent containing a coordination-bonding functional group that forms a coordination bond with a rare earth element ion, bonded to the linker group, or has a linker group containing a coordination-bonding functional group that forms a coordination bond with a rare earth element ion.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C09D 201/00 - Coating compositions based on unspecified macromolecular compounds
• C09D 7/61 - Additives non-macromolecular inorganic

Abstract

The present invention addresses the problem of providing mechanochemical reaction additive that can be handled in air, that can be easily synthesized, that when used in a mechanochemical reaction can increase the activity of the mechanochemical reaction, and that can be applied to a wide variety of substrates under gentle conditions. Provided as a solution is a mechanochemical reaction additive comprising at least a ligand compound (Lx) or a salt thereof, wherein the ligand compound (Lx) is one or more compounds from among phosphorus-based compounds, bipyridine compounds, and N-heterocyclic carbene-based compounds, the ligand compound (Lx) has a polymer chain in the molecule thereof, and the polymer chain is one or more polymer chains from among polyethers, polyamides, polyesters, and polyurethanes.

IPC Classes  ?

• C07B 61/00 - Other general methods
• C07B 37/04 - Substitution
• C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
• C07C 43/20 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
• C07C 43/205 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
• C07C 43/21 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing rings other than six-membered aromatic rings
• C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
• C07C 45/68 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by isomerisationPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by change of size of the carbon skeleton by increase in the number of carbon atoms
• C07C 49/517 - Saturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups
• C07C 49/84 - Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
• C07F 9/50 - Organo-phosphines
• C08G 65/327 - Polymers modified by chemical after-treatment with inorganic compounds containing phosphorus

Abstract

The embolic agent according to the present invention is a copolymer formed from a cationic functional group-containing monomer and an aromatic group-containing monomer, said embolic agent having, as an active ingredient, a copolymer which at least partly has a structure expressed by general formula (I) (In the formula, R11and R12represent a hydrogen atom or an alkyl group, which has 1 to 20 carbon atoms and may have a substituent, and satisfy the relational expression R11=R12. Y11and Y12independently represent a single bond or an alkylene group which has 1 to 20 carbon atoms. Ar11represents an aromatic hydrocarbon group which has 6 to 16 carbon atoms and may have a substituent. X11 represents an ammonium group or an amino group. n11 represents an integer of 10 to 1,000.)

IPC Classes  ?

• A61L 31/04 - Macromolecular materials
• A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 31/14 - Materials characterised by their function or physical properties
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 35/00 - Antineoplastic agents
• C08F 220/10 - Esters